Last reviewed · How we verify
alpha-blocker and NSAID
alpha-blocker and NSAID is a Alpha-blocker and NSAID combination Small molecule drug developed by Samsung Medical Center. It is currently FDA-approved for Lower urinary tract symptoms associated with benign prostatic hyperplasia, Dysuria and urinary discomfort. Also known as: tamsulosin and celecoxib, alfuzosin and celecoxib, doxazosin and celecoxib, terazosin and celecoxib.
This combination blocks alpha-adrenergic receptors to relax smooth muscle in the urinary tract while inhibiting cyclooxygenase enzymes to reduce inflammation and pain.
This combination blocks alpha-adrenergic receptors to relax smooth muscle in the urinary tract while inhibiting cyclooxygenase enzymes to reduce inflammation and pain. Used for Lower urinary tract symptoms associated with benign prostatic hyperplasia, Dysuria and urinary discomfort.
At a glance
| Generic name | alpha-blocker and NSAID |
|---|---|
| Also known as | tamsulosin and celecoxib, alfuzosin and celecoxib, doxazosin and celecoxib, terazosin and celecoxib |
| Sponsor | Samsung Medical Center |
| Drug class | Alpha-blocker and NSAID combination |
| Target | Alpha-1 adrenergic receptor; COX-1 and COX-2 enzymes |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | FDA-approved |
Mechanism of action
Alpha-blockers relax smooth muscle in the prostate and bladder neck, improving urinary flow and reducing lower urinary tract symptoms. NSAIDs inhibit prostaglandin synthesis by blocking COX-1 and COX-2 enzymes, providing anti-inflammatory and analgesic effects. Together, they address both obstructive and inflammatory components of urological conditions.
Approved indications
- Lower urinary tract symptoms associated with benign prostatic hyperplasia
- Dysuria and urinary discomfort
Common side effects
- Dizziness
- Headache
- Gastrointestinal upset
- Orthostatic hypotension
- Dyspepsia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- alpha-blocker and NSAID CI brief — competitive landscape report
- alpha-blocker and NSAID updates RSS · CI watch RSS
- Samsung Medical Center portfolio CI
Frequently asked questions about alpha-blocker and NSAID
What is alpha-blocker and NSAID?
How does alpha-blocker and NSAID work?
What is alpha-blocker and NSAID used for?
Who makes alpha-blocker and NSAID?
Is alpha-blocker and NSAID also known as anything else?
What drug class is alpha-blocker and NSAID in?
What development phase is alpha-blocker and NSAID in?
What are the side effects of alpha-blocker and NSAID?
What does alpha-blocker and NSAID target?
Related
- Drug class: All Alpha-blocker and NSAID combination drugs
- Target: All drugs targeting Alpha-1 adrenergic receptor; COX-1 and COX-2 enzymes
- Manufacturer: Samsung Medical Center — full pipeline
- Therapeutic area: All drugs in Urology
- Indication: Drugs for Lower urinary tract symptoms associated with benign prostatic hyperplasia
- Indication: Drugs for Dysuria and urinary discomfort
- Also known as: tamsulosin and celecoxib, alfuzosin and celecoxib, doxazosin and celecoxib, terazosin and celecoxib
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing